{"id":202833,"date":"2023-12-06T16:47:00","date_gmt":"2023-12-06T08:47:00","guid":{"rendered":"https:\/\/pingtungtimes.com.tw\/?p=202833"},"modified":"2023-12-06T16:47:00","modified_gmt":"2023-12-06T08:47:00","slug":"%e5%ae%a2%e8%a7%80%e7%b7%a9%e8%a7%a3%e7%8e%87%e9%81%9445-8%ef%bc%8c%e9%bd%8a%e9%ad%af%e8%a3%bd%e8%97%a5%e8%89%be%e5%b8%95%e6%b4%9b%e5%88%a9%e5%96%ae%e6%8a%97%e5%96%ae%e8%97%a5%e6%b2%bb%e7%99%82","status":"publish","type":"post","link":"https:\/\/pingtungtimes.com.tw\/?p=202833","title":{"rendered":"\u5ba2\u89c0\u7de9\u89e3\u7387\u905445.8%\uff0c\u9f4a\u9b6f\u88fd\u85e5\u827e\u5e15\u6d1b\u5229\u55ae\u6297\u55ae\u85e5\u6cbb\u7642\u665a\u671f\u5be6\u9ad4\u7624II\u671f\u7814\u7a76\u7d50\u679c\u5728ESMO\u4e9e\u6d32\u5e74\u6703\u516c\u4f48"},"content":{"rendered":"<div>\n<table name=\"logo_release\" border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><span class=\"legendSpanClass\">\u6fdf\u5357<\/span><span class=\"legendSpanClass\">2023\u5e7412\u67086\u65e5<\/span> \/\u7f8e\u901a\u793e\/ &#8212; 12\u67081\u81f33\u65e5\uff0c\u57282023\u5e74\u6b50\u6d32\u816b\u7624\u5167\u79d1\u5b78\u6703\u4e9e\u6d32\u5e74\u6703\uff08ESMO Asia\uff09\u4e0a\uff0c\u9f4a\u9b6f\u88fd\u85e5\u4ee5\u58c1\u5831\u5f62\u5f0f\u5831\u544a\u4e861\u985e\u65b0\u85e5\u827e\u5e15\u6d1b\u5229\u55ae\u6297\uff08QL1604\uff09\u55ae\u85e5\u6cbb\u7642\u4e0d\u53ef\u5207\u9664\u6216\u8f49\u79fb\u6027dMMR\/MSI-H\u5be6\u9ad4\u7624\u7684\u55ae\u81c2\u3001II\u671f\u95dc\u9375\u81e8\u5e8a\u7814\u7a76\u6700\u65b0\u7d50\u679c\u3002\u4e3b\u8981\u7814\u7a76\u8005\u70ba\u5fa9\u65e6\u5927\u5b78\u9644\u5c6c\u816b\u7624\u91ab\u9662\u90ed\u5049\u528d\u6559\u6388\u548c\u56db\u5ddd\u5927\u5b78\u83ef\u897f\u91ab\u9662\u7562\u92d2\u6559\u6388\u3002<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<\/p><\/div>\n<p>\u827e\u5e15\u6d1b\u5229\u55ae\u6297\u662f\u4e00\u7a2e\u8207PD-1\u7d50\u5408\u7684\u9ad8\u9078\u64c7\u6027\u4eba\u6e90\u5316\u55ae\u514b\u9686\u6297\u9ad4\u3002\u7814\u7a76\u7d50\u679c\u986f\u793a\uff0c\u827e\u5e15\u6d1b\u5229\u55ae\u6297\u55ae\u85e5\u6cbb\u7642\u4e0d\u53ef\u5207\u9664\u6216\u8f49\u79fb\u6027dMMR\/MSI-H\u5be6\u9ad4\u7624\u5177\u6709\u826f\u597d\u7684\u7642\u6548\uff0c\u7368\u7acb\u5f71\u50cf\u8a55\u4f30\u59d4\u54e1\u6703\uff08IRRC\uff09\u8a55\u4f30\u7684\u5168\u4eba\u7fa4\u5ba2\u89c0\u7de9\u89e3\u7387\uff08ORR\uff09\u70ba45.8% (95%CI\uff0c 36.7-55.2)\uff0c\u8d85\u904e\u9810\u8a2d\u4e3b\u8981\u7814\u7a76\u7d42\u9ede\u3002<\/p>\n<p><b>\u4e00\u3001<\/b><b>\u7814\u7a76\u80cc\u666f<\/b><\/p>\n<p>DNA\u932f\u914d\u4fee\u5fa9\u7f3a\u9677\uff08dMMR\uff09\u6216\u9ad8\u5ea6\u5fae\u885b\u661f\u4e0d\u7a69\u5b9a\uff08MSI-H\uff09\u662f\u5be6\u9ad4\u7624\u7684\u7368\u7279\u8868\u578b<sup>[1]<\/sup>\u3002DNA\u8907\u88fd\u904e\u7a0b\u4e2d\uff0c\u5fae\u885b\u661f\u5e8f\u5217\u6700\u6613\u767c\u751f\u932f\u914d\uff0c\u9700\u8981\u9032\u884c\u932f\u914d\u4fee\u5fa9\uff0cdMMR\u53ef\u5c0e\u81f4\u79fb\u78bc\u7a81\u8b8a\uff0c\u5f15\u8d77\u5fae\u885b\u661f\u4e0d\u7a69\u5b9a\uff08MSI\uff09\u3002dMMR\/MSI-H\u5be6\u9ad4\u7624\u5c0d\u514d\u75ab\u6aa2\u67e5\u9ede\u6291\u5236\u5291\u6cbb\u7642\u53cd\u61c9\u826f\u597d\uff0c\u7a0b\u5e8f\u6027\u6b7b\u4ea1\u53d7\u9ad4-1\uff08PD-1\uff09\u6216\u7a0b\u5e8f\u6027\u6b7b\u4ea1\u914d\u9ad4-1\uff08PD-L1\uff09\u6291\u5236\u5291\u6cbb\u7642dMMR\/MSI-H\u5be6\u9ad4\u7624\u5177\u6709\u8f03\u9ad8\u7684\u5ba2\u89c0\u7de9\u89e3\u7387\uff08ORR\uff09\uff0c\u4e26\u4e14\u7de9\u89e3\u6301\u7e8c\u6642\u9593\u9577<sup>[2-3]<\/sup>\u3002<\/p>\n<p>\u827e\u5e15\u6d1b\u5229\u55ae\u6297\u6cbb\u7642\u665a\u671f\u5be6\u9ad4\u7624\u7684I\u671f\u7814\u7a76\u8868\u73fe\u51fa\u826f\u597d\u7684\u5b89\u5168\u6027\u548c\u6297\u816b\u7624\u6d3b\u6027\uff0c\u5728\u63a5\u53d7\u827e\u5e15\u6d1b\u5229\u55ae\u62970.3-3 mg\/kg Q3W\u7684\u6240\u6709\u60a3\u8005\u4e2d\uff0cORR\u9054\u523020%<sup>[4]<\/sup>\u3002\u672c\u95dc\u9375\u7814\u7a76\u65e8\u5728\u8a55\u4f30\u827e\u5e15\u6d1b\u5229\u55ae\u6297\u55ae\u85e5\u6cbb\u7642\u4e0d\u53ef\u5207\u9664\u6216\u8f49\u79fb\u6027dMMR\/MSI-H\u5be6\u9ad4\u7624\u7684\u7642\u6548\u548c\u5b89\u5168\u6027\u3002<\/p>\n<p><b>\u4e8c\u3001<\/b><b>\u7814\u7a76\u8a2d\u8a08\u548c\u65b9\u6cd5<\/b><\/p>\n<p>\u672c\u7814\u7a76\u70ba\u55ae\u81c2\u3001II\u671f\u95dc\u9375\u81e8\u5e8a\u7814\u7a76\uff0c\u7d0d\u5165\u4e0d\u53ef\u5207\u9664\u6216\u8f49\u79fb\u6027\u7d93\u7d44\u7e54\u75c5\u7406\u5b78\u6216\u7d30\u80de\u5b78\u78ba\u8a8d\u7684dMMR\/MSI-H\u5be6\u9ad4\u7624\u60a3\u8005\uff0c\u63a5\u53d7\u827e\u5e15\u6d1b\u5229\u55ae\u6297\u55ae\u85e5\u6cbb\u7642\uff0c\u7d66\u85e5\u65b9\u6848\u70ba200 mg\u56fa\u5b9a\u5291\u91cf\uff08\u5982\u679c\u53d7\u8a66\u8005\u9ad4\u91cd\uff1c40 kg\uff0c\u7d66\u85e5\u5291\u91cf\u70ba3 mg\/kg\uff09\uff0c\u975c\u8108\u6ef4\u6ce8\uff0c\u6bcf3\u5468\u7d66\u85e51\u6b21\u3002\u60a3\u8005\u63a5\u53d7\u827e\u5e15\u6d1b\u5229\u55ae\u6297\u6cbb\u7642\u76f4\u81f3\u75be\u75c5\u9032\u5c55\u3001\u51fa\u73fe\u4e0d\u53ef\u8010\u53d7\u7684\u6bd2\u6027\u3001\u958b\u59cb\u65b0\u7684\u6297\u816b\u7624\u6cbb\u7642\u3001\u6b7b\u4ea1\u3001\u64a4\u56de\u77e5\u60c5\u540c\u610f\u7b49\u539f\u56e0\uff0c\u6700\u9577\u6cbb\u7642\u6642\u9593\u4e0d\u8d85\u904e2\u5e74\u3002\u6cbb\u7642\u7d50\u675f\u5f8c\uff0c\u5c0d\u60a3\u8005\u9032\u884c\u751f\u5b58\u96a8\u8a2a\u3002\u7814\u7a76\u7684\u4e3b\u8981\u7d42\u9ede\u70baIRRC\u6839\u64da\u5be6\u9ad4\u816b\u7624\u7642\u6548\u8a55\u50f9\u6a19\u6e96\uff081.1\u7248\uff09\u8a55\u4f30\u7684ORR\u3002\u7814\u7a76\u8a2d\u8a08\u5982\u4e0b\u5716\u6240\u793a\u3002<\/p>\n<p><b>\u4e09\u3001<\/b><b>\u7814\u7a76\u7d50\u679c<\/b><\/p>\n<p>\u5f9e2020\u5e746\u6708\u81f32023\u5e741\u6708\uff0c\u7814\u7a76\u5171\u7d0d\u5165120\u4f8bdMMR\/MSI-H\u5be6\u9ad4\u7624\u60a3\u8005\uff0c\u5176\u4e2d\u7d50\u76f4\u8178\u764c\u60a3\u800580\u4f8b\uff0866.7%\uff09\uff0c\u80c3\u764c\u60a3\u800518\u4f8b\uff0815.0%\uff09\uff0c\u5176\u5b83\u5be6\u9ad4\u7624\u60a3\u800522\u4f8b\uff0818.3%\uff09\uff1b97.5%\u7684\u60a3\u8005\u5728\u5165\u7d44\u6642\u75be\u75c5\u5206\u671f\u70baIV\u671f\uff0c\u4e2d\u4f4d\u6cbb\u7642\u7dda\u6578\u70ba2.0\uff08\u7bc4\u570d\uff0c0\u20136\uff09\u3002<\/p>\n<p>\u5728\u7642\u6548\u65b9\u9762\uff0c\u622a\u81f32023\u5e747\u670820\u65e5\uff0c\u4e2d\u4f4d\u96a8\u8a2a\u6642\u9593\u70ba13.6\u500b\u6708\uff0c\u670911\u4f8b\u60a3\u8005\u9054\u5230\u5b8c\u5168\u7de9\u89e3\uff08CR\uff09\uff0c44\u4f8b\u60a3\u8005\u9054\u5230\u90e8\u5206\u7de9\u89e3\uff08PR\uff09\uff0cORR\u70ba45.8%\uff0895% CI: 36.7%\u201355.2%\uff09\uff0c\u75be\u75c5\u63a7\u5236\u7387\uff08DCR\uff09\u70ba77.5%\uff0895% CI: 69.0%\u201384.6%\uff09\u3002\u5728\u7d50\u76f4\u8178\u764c\u60a3\u8005\u4e2d\uff0cORR\u548cDCR\u5206\u5225\u70ba42.5%\uff0895% CI: 31.5%\u201354.1%\uff09\u548c77.5%\uff0895% CI: 31.5%\u201354.1%\uff09\u3002\u4e2d\u4f4d\u7de9\u89e3\u6301\u7e8c\u6642\u9593\uff08DoR\uff09\u5c1a\u672a\u9054\u5230\uff0c6\u500b\u6708\u548c12\u500b\u6708DoR\u7387\u5206\u5225\u70ba100%\u548c97.4%\uff1b\u4e2d\u4f4d\u7121\u9032\u5c55\u751f\u5b58\u671f\uff08PFS\uff09\u548c\u4e2d\u4f4d\u7e3d\u751f\u5b58\u671f\uff08OS\uff09\u672a\u9054\u5230\u3002\u7de9\u89e3\u60a3\u8005\u7684\u9776\u75c5\u7076\u6700\u4f73\u8b8a\u5316\u60c5\u6cc1\u5982\u4e0b\u5716\u6240\u793a\u3002<\/p>\n<p><b>\u56db\u3001<\/b><b>\u5c0f\u7d50<\/b><\/p>\n<p>\u827e\u5e15\u6d1b\u5229\u55ae\u6297\u55ae\u85e5\u6cbb\u7642\u4e0d\u53ef\u5207\u9664\u6216\u8f49\u79fb\u6027dMMR\/MSI-H\u5be6\u9ad4\u7624\u5177\u6709\u826f\u597d\u7684\u7642\u6548\u548c\u5b89\u5168\u6027\u3002\u9f4a\u9b6f\u88fd\u85e5\u827e\u5e15\u6d1b\u5229\u55ae\u6297\u4e0a\u5e02\u7533\u8acb\u5df2\u65bc\u4eca\u5e749\u6708\u7372\u5f97CDE\u53d7\u7406\u3002<\/p>\n<div>\n<table border=\"0\" cellspacing=\"0\" cellpadding=\"1\" class=\"prnbcc\">\n<tbody>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnews_p\"><span class=\"prnews_span\"><b>\u53c3\u8003\u6587\u737b\uff1a<\/b><\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">1. Bhamidipati D, Subbiah V. Tumor-agnostic drug development in dMMR\/MSI-H solid tumors. Trends Cancer. 2023;9(10):828-839.<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">2. Le DT, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">3. Li J, et al. Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair\/microsatellite instability high solid tumors. J Hematol Oncol. 2021;14(1):95.<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">4. Huang Z, et al. A first-in-human, open-label, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, pharmacokinetics\/pharmacodynamics, and antitumor activity of QL1604, a humanized anti-PD-1 mAb, in patients with advanced or metastatic solid tumors. Front Immunol. 2023;14:1258573.<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>\u00a0<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>\u6fdf\u53572023\u5e7412\u67086\u65e5 \/\u7f8e&#8230;<\/p>\n","protected":false},"author":16,"featured_media":202834,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"fifu_image_url":"","fifu_image_alt":"","footnotes":""},"categories":[40567],"tags":[],"class_list":["post-202833","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-40567"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>\u5ba2\u89c0\u7de9\u89e3\u7387\u905445.8%\uff0c\u9f4a\u9b6f\u88fd\u85e5\u827e\u5e15\u6d1b\u5229\u55ae\u6297\u55ae\u85e5\u6cbb\u7642\u665a\u671f\u5be6\u9ad4\u7624II\u671f\u7814\u7a76\u7d50\u679c\u5728ESMO\u4e9e\u6d32\u5e74\u6703\u516c\u4f48 - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831<\/title>\n<meta name=\"description\" content=\"\u6fdf\u53572023\u5e7412\u67086\u65e5 \/\u7f8e\u901a\u793e\/ -- 12\u67081\u81f33\u65e5\uff0c\u57282023\u5e74\u6b50\u6d32\u816b\u7624\u5167\u79d1\u5b78\u6703\u4e9e\u6d32\u5e74\u6703\uff08ESMO Asia\uff09\u4e0a\uff0c\u9f4a\u9b6f\u88fd\u85e5\u4ee5\u58c1\u5831\u5f62\u5f0f\u5831\u544a\u4e861\u985e\u65b0\u85e5\u827e\u5e15\u6d1b\u5229\u55ae\u6297\uff08QL1604\uff09\u55ae\u85e5\u6cbb\u7642\u4e0d\u53ef\u5207\u9664\u6216\u8f49\u79fb\u6027dMMR\/MSI-H\u5be6\u9ad4\u7624\u7684\u55ae\u81c2\u3001II\u671f\u95dc\u9375\u81e8\u5e8a\u7814\u7a76\u6700\u65b0\u7d50\u679c\u3002\u4e3b\u8981\u7814\u7a76\u8005\u70ba\u5fa9\u65e6\u5927\u5b78\u9644\u5c6c\u816b\u7624\u91ab\u9662\u90ed\u5049\u528d\u6559\u6388\u548c\u56db\u5ddd\u5927\u5b78\u83ef\u897f\u91ab\u9662\u7562\u92d2\u6559\u6388\u3002     \u827e\u5e15\u6d1b\u5229\u55ae\u6297\u662f\u4e00\u7a2e\u8207PD-1\u7d50\u5408\u7684\u9ad8\u9078\u64c7\u6027\u4eba\u6e90\u5316\u55ae\u514b\u9686\u6297\u9ad4\u3002\u7814\u7a76\u7d50\u679c\u986f\u793a\uff0c\u827e\u5e15\u6d1b\u5229\u55ae\u6297\u55ae\u85e5\u6cbb\u7642\u4e0d\u53ef\u5207\u9664\u6216\u8f49\u79fb\u6027dMMR\/MSI-H\u5be6\u9ad4\u7624\u5177\u6709\u826f\u597d\u7684\u7642\u6548\uff0c\u7368\u7acb\u5f71\u50cf\u8a55\u4f30\u59d4\u54e1\u6703\uff08IRRC\uff09\u8a55\u4f30\u7684\u5168\u4eba\u7fa4\u5ba2\u89c0\u7de9\u89e3\u7387\uff08ORR\uff09\u70ba45.8% (95%CI\uff0c 36.7-55.2)\uff0c\u8d85\u904e\u9810\u8a2d\u4e3b\u8981\u7814\u7a76\u7d42\u9ede\u3002 \u4e00\u3001\u7814\u7a76\u80cc\u666f DNA\u932f\u914d\u4fee\u5fa9\u7f3a\u9677\uff08dMMR\uff09\u6216\u9ad8\u5ea6\u5fae\u885b\u661f\u4e0d\u7a69\u5b9a\uff08MSI-H\uff09\u662f\u5be6\u9ad4\u7624\u7684\u7368\u7279\u8868\u578b\u3002DNA\u8907\u88fd\u904e\u7a0b\u4e2d\uff0c\u5fae\u885b\u661f\u5e8f\u5217\u6700\u6613\u767c\u751f\u932f\u914d\uff0c\u9700\u8981\u9032\u884c\u932f\u914d\u4fee\u5fa9\uff0cdMMR\u53ef\u5c0e\u81f4\u79fb\u78bc\u7a81\u8b8a\uff0c\u5f15\u8d77\u5fae\u885b\u661f\u4e0d\u7a69\u5b9a\uff08MSI\uff09\u3002dMMR\/MSI-H\u5be6\u9ad4\u7624\u5c0d\u514d\u75ab\u6aa2\u67e5\u9ede\u6291\u5236\u5291\u6cbb\u7642\u53cd\u61c9\u826f\u597d\uff0c\u7a0b\u5e8f\u6027\u6b7b\u4ea1\u53d7\u9ad4-1\uff08PD-1\uff09\u6216\u7a0b\u5e8f\u6027\u6b7b\u4ea1\u914d\u9ad4-1\uff08PD-L1\uff09\u6291\u5236\u5291\u6cbb\u7642dMMR\/MSI-H\u5be6\u9ad4\u7624\u5177\u6709\u8f03\u9ad8\u7684\u5ba2\u89c0\u7de9\u89e3\u7387\uff08ORR\uff09\uff0c\u4e26\u4e14\u7de9\u89e3\u6301\u7e8c\u6642\u9593\u9577\u3002 \u827e\u5e15\u6d1b\u5229\u55ae\u6297\u6cbb\u7642\u665a\u671f\u5be6\u9ad4\u7624\u7684I\u671f\u7814\u7a76\u8868\u73fe\u51fa\u826f\u597d\u7684\u5b89\u5168\u6027\u548c\u6297\u816b\u7624\u6d3b\u6027\uff0c\u5728\u63a5\u53d7\u827e\u5e15\u6d1b\u5229\u55ae\u62970.3-3 mg\/kg Q3W\u7684\u6240\u6709\u60a3\u8005\u4e2d\uff0cORR\u9054\u523020%\u3002\u672c\u95dc\u9375\u7814\u7a76\u65e8\u5728\u8a55\u4f30\u827e\u5e15\u6d1b\u5229\u55ae\u6297\u55ae\u85e5\u6cbb\u7642\u4e0d\u53ef\u5207\u9664\u6216\u8f49\u79fb\u6027dMMR\/MSI-H\u5be6\u9ad4\u7624\u7684\u7642\u6548\u548c\u5b89\u5168\u6027\u3002 \u4e8c\u3001\u7814\u7a76\u8a2d\u8a08\u548c\u65b9\u6cd5 \u672c\u7814\u7a76\u70ba\u55ae\u81c2\u3001II\u671f\u95dc\u9375\u81e8\u5e8a\u7814\u7a76\uff0c\u7d0d\u5165\u4e0d\u53ef\u5207\u9664\u6216\u8f49\u79fb\u6027\u7d93\u7d44\u7e54\u75c5\u7406\u5b78\u6216\u7d30\u80de\u5b78\u78ba\u8a8d\u7684dMMR\/MSI-H\u5be6\u9ad4\u7624\u60a3\u8005\uff0c\u63a5\u53d7\u827e\u5e15\u6d1b\u5229\u55ae\u6297\u55ae\u85e5\u6cbb\u7642\uff0c\u7d66\u85e5\u65b9\u6848\u70ba200 mg\u56fa\u5b9a\u5291\u91cf\uff08\u5982\u679c\u53d7\u8a66\u8005\u9ad4\u91cd\uff1c40 kg\uff0c\u7d66\u85e5\u5291\u91cf\u70ba3 mg\/kg\uff09\uff0c\u975c\u8108\u6ef4\u6ce8\uff0c\u6bcf3\u5468\u7d66\u85e51\u6b21\u3002\u60a3\u8005\u63a5\u53d7\u827e\u5e15\u6d1b\u5229\u55ae\u6297\u6cbb\u7642\u76f4\u81f3\u75be\u75c5\u9032\u5c55\u3001\u51fa\u73fe\u4e0d\u53ef\u8010\u53d7\u7684\u6bd2\u6027\u3001\u958b\u59cb\u65b0\u7684\u6297\u816b\u7624\u6cbb\u7642\u3001\u6b7b\u4ea1\u3001\u64a4\u56de\u77e5\u60c5\u540c\u610f\u7b49\u539f\u56e0\uff0c\u6700\u9577\u6cbb\u7642\u6642\u9593\u4e0d\u8d85\u904e2\u5e74\u3002\u6cbb\u7642\u7d50\u675f\u5f8c\uff0c\u5c0d\u60a3\u8005\u9032\u884c\u751f\u5b58\u96a8\u8a2a\u3002\u7814\u7a76\u7684\u4e3b\u8981\u7d42\u9ede\u70baIRRC\u6839\u64da\u5be6\u9ad4\u816b\u7624\u7642\u6548\u8a55\u50f9\u6a19\u6e96\uff081.1\u7248\uff09\u8a55\u4f30\u7684ORR\u3002\u7814\u7a76\u8a2d\u8a08\u5982\u4e0b\u5716\u6240\u793a\u3002 \u4e09\u3001\u7814\u7a76\u7d50\u679c \u5f9e2020\u5e746\u6708\u81f32023\u5e741\u6708\uff0c\u7814\u7a76\u5171\u7d0d\u5165120\u4f8bdMMR\/MSI-H\u5be6\u9ad4\u7624\u60a3\u8005\uff0c\u5176\u4e2d\u7d50\u76f4\u8178\u764c\u60a3\u800580\u4f8b\uff0866.7%\uff09\uff0c\u80c3\u764c\u60a3\u800518\u4f8b\uff0815.0%\uff09\uff0c\u5176\u5b83\u5be6\u9ad4\u7624\u60a3\u800522\u4f8b\uff0818.3%\uff09\uff1b97.5%\u7684\u60a3\u8005\u5728\u5165\u7d44\u6642\u75be\u75c5\u5206\u671f\u70baIV\u671f\uff0c\u4e2d\u4f4d\u6cbb\u7642\u7dda\u6578\u70ba2.0\uff08\u7bc4\u570d\uff0c0\u20136\uff09\u3002 \u5728\u7642\u6548\u65b9\u9762\uff0c\u622a\u81f32023\u5e747\u670820\u65e5\uff0c\u4e2d\u4f4d\u96a8\u8a2a\u6642\u9593\u70ba13.6\u500b\u6708\uff0c\u670911\u4f8b\u60a3\u8005\u9054\u5230\u5b8c\u5168\u7de9\u89e3\uff08CR\uff09\uff0c44\u4f8b\u60a3\u8005\u9054\u5230\u90e8\u5206\u7de9\u89e3\uff08PR\uff09\uff0cORR\u70ba45.8%\uff0895% CI: 36.7%\u201355.2%\uff09\uff0c\u75be\u75c5\u63a7\u5236\u7387\uff08DCR\uff09\u70ba77.5%\uff0895% CI: 69.0%\u201384.6%\uff09\u3002\u5728\u7d50\u76f4\u8178\u764c\u60a3\u8005\u4e2d\uff0cORR\u548cDCR\u5206\u5225\u70ba42.5%\uff0895% CI: 31.5%\u201354.1%\uff09\u548c77.5%\uff0895% CI: 31.5%\u201354.1%\uff09\u3002\u4e2d\u4f4d\u7de9\u89e3\u6301\u7e8c\u6642\u9593\uff08DoR\uff09\u5c1a\u672a\u9054\u5230\uff0c6\u500b\u6708\u548c12\u500b\u6708DoR\u7387\u5206\u5225\u70ba100%\u548c97.4%\uff1b\u4e2d\u4f4d\u7121\u9032\u5c55\u751f\u5b58\u671f\uff08PFS\uff09\u548c\u4e2d\u4f4d\u7e3d\u751f\u5b58\u671f\uff08OS\uff09\u672a\u9054\u5230\u3002\u7de9\u89e3\u60a3\u8005\u7684\u9776\u75c5\u7076\u6700\u4f73\u8b8a\u5316\u60c5\u6cc1\u5982\u4e0b\u5716\u6240\u793a\u3002 \u56db\u3001\u5c0f\u7d50 \u827e\u5e15\u6d1b\u5229\u55ae\u6297\u55ae\u85e5\u6cbb\u7642\u4e0d\u53ef\u5207\u9664\u6216\u8f49\u79fb\u6027dMMR\/MSI-H\u5be6\u9ad4\u7624\u5177\u6709\u826f\u597d\u7684\u7642\u6548\u548c\u5b89\u5168\u6027\u3002\u9f4a\u9b6f\u88fd\u85e5\u827e\u5e15\u6d1b\u5229\u55ae\u6297\u4e0a\u5e02\u7533\u8acb\u5df2\u65bc\u4eca\u5e749\u6708\u7372\u5f97CDE\u53d7\u7406\u3002   \u53c3\u8003\u6587\u737b\uff1a   1. Bhamidipati D, Subbiah V. Tumor-agnostic drug development in dMMR\/MSI-H solid tumors. Trends Cancer. 2023;9(10):828-839.   2. Le DT, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.   3. Li J, et al. Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair\/microsatellite instability high solid tumors. J Hematol Oncol. 2021;14(1):95.   4. Huang Z, et al. A first-in-human, open-label, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, pharmacokinetics\/pharmacodynamics, and antitumor activity of QL1604, a humanized anti-PD-1 mAb, in patients with advanced or metastatic solid tumors. Front Immunol. 2023;14:1258573.    \u00a0\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pingtungtimes.com.tw\/?p=202833\" \/>\n<meta property=\"og:locale\" content=\"zh_TW\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\u5ba2\u89c0\u7de9\u89e3\u7387\u905445.8%\uff0c\u9f4a\u9b6f\u88fd\u85e5\u827e\u5e15\u6d1b\u5229\u55ae\u6297\u55ae\u85e5\u6cbb\u7642\u665a\u671f\u5be6\u9ad4\u7624II\u671f\u7814\u7a76\u7d50\u679c\u5728ESMO\u4e9e\u6d32\u5e74\u6703\u516c\u4f48 - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\" \/>\n<meta property=\"og:description\" content=\"\u6fdf\u53572023\u5e7412\u67086\u65e5 \/\u7f8e\u901a\u793e\/ -- 12\u67081\u81f33\u65e5\uff0c\u57282023\u5e74\u6b50\u6d32\u816b\u7624\u5167\u79d1\u5b78\u6703\u4e9e\u6d32\u5e74\u6703\uff08ESMO Asia\uff09\u4e0a\uff0c\u9f4a\u9b6f\u88fd\u85e5\u4ee5\u58c1\u5831\u5f62\u5f0f\u5831\u544a\u4e861\u985e\u65b0\u85e5\u827e\u5e15\u6d1b\u5229\u55ae\u6297\uff08QL1604\uff09\u55ae\u85e5\u6cbb\u7642\u4e0d\u53ef\u5207\u9664\u6216\u8f49\u79fb\u6027dMMR\/MSI-H\u5be6\u9ad4\u7624\u7684\u55ae\u81c2\u3001II\u671f\u95dc\u9375\u81e8\u5e8a\u7814\u7a76\u6700\u65b0\u7d50\u679c\u3002\u4e3b\u8981\u7814\u7a76\u8005\u70ba\u5fa9\u65e6\u5927\u5b78\u9644\u5c6c\u816b\u7624\u91ab\u9662\u90ed\u5049\u528d\u6559\u6388\u548c\u56db\u5ddd\u5927\u5b78\u83ef\u897f\u91ab\u9662\u7562\u92d2\u6559\u6388\u3002     \u827e\u5e15\u6d1b\u5229\u55ae\u6297\u662f\u4e00\u7a2e\u8207PD-1\u7d50\u5408\u7684\u9ad8\u9078\u64c7\u6027\u4eba\u6e90\u5316\u55ae\u514b\u9686\u6297\u9ad4\u3002\u7814\u7a76\u7d50\u679c\u986f\u793a\uff0c\u827e\u5e15\u6d1b\u5229\u55ae\u6297\u55ae\u85e5\u6cbb\u7642\u4e0d\u53ef\u5207\u9664\u6216\u8f49\u79fb\u6027dMMR\/MSI-H\u5be6\u9ad4\u7624\u5177\u6709\u826f\u597d\u7684\u7642\u6548\uff0c\u7368\u7acb\u5f71\u50cf\u8a55\u4f30\u59d4\u54e1\u6703\uff08IRRC\uff09\u8a55\u4f30\u7684\u5168\u4eba\u7fa4\u5ba2\u89c0\u7de9\u89e3\u7387\uff08ORR\uff09\u70ba45.8% (95%CI\uff0c 36.7-55.2)\uff0c\u8d85\u904e\u9810\u8a2d\u4e3b\u8981\u7814\u7a76\u7d42\u9ede\u3002 \u4e00\u3001\u7814\u7a76\u80cc\u666f DNA\u932f\u914d\u4fee\u5fa9\u7f3a\u9677\uff08dMMR\uff09\u6216\u9ad8\u5ea6\u5fae\u885b\u661f\u4e0d\u7a69\u5b9a\uff08MSI-H\uff09\u662f\u5be6\u9ad4\u7624\u7684\u7368\u7279\u8868\u578b\u3002DNA\u8907\u88fd\u904e\u7a0b\u4e2d\uff0c\u5fae\u885b\u661f\u5e8f\u5217\u6700\u6613\u767c\u751f\u932f\u914d\uff0c\u9700\u8981\u9032\u884c\u932f\u914d\u4fee\u5fa9\uff0cdMMR\u53ef\u5c0e\u81f4\u79fb\u78bc\u7a81\u8b8a\uff0c\u5f15\u8d77\u5fae\u885b\u661f\u4e0d\u7a69\u5b9a\uff08MSI\uff09\u3002dMMR\/MSI-H\u5be6\u9ad4\u7624\u5c0d\u514d\u75ab\u6aa2\u67e5\u9ede\u6291\u5236\u5291\u6cbb\u7642\u53cd\u61c9\u826f\u597d\uff0c\u7a0b\u5e8f\u6027\u6b7b\u4ea1\u53d7\u9ad4-1\uff08PD-1\uff09\u6216\u7a0b\u5e8f\u6027\u6b7b\u4ea1\u914d\u9ad4-1\uff08PD-L1\uff09\u6291\u5236\u5291\u6cbb\u7642dMMR\/MSI-H\u5be6\u9ad4\u7624\u5177\u6709\u8f03\u9ad8\u7684\u5ba2\u89c0\u7de9\u89e3\u7387\uff08ORR\uff09\uff0c\u4e26\u4e14\u7de9\u89e3\u6301\u7e8c\u6642\u9593\u9577\u3002 \u827e\u5e15\u6d1b\u5229\u55ae\u6297\u6cbb\u7642\u665a\u671f\u5be6\u9ad4\u7624\u7684I\u671f\u7814\u7a76\u8868\u73fe\u51fa\u826f\u597d\u7684\u5b89\u5168\u6027\u548c\u6297\u816b\u7624\u6d3b\u6027\uff0c\u5728\u63a5\u53d7\u827e\u5e15\u6d1b\u5229\u55ae\u62970.3-3 mg\/kg Q3W\u7684\u6240\u6709\u60a3\u8005\u4e2d\uff0cORR\u9054\u523020%\u3002\u672c\u95dc\u9375\u7814\u7a76\u65e8\u5728\u8a55\u4f30\u827e\u5e15\u6d1b\u5229\u55ae\u6297\u55ae\u85e5\u6cbb\u7642\u4e0d\u53ef\u5207\u9664\u6216\u8f49\u79fb\u6027dMMR\/MSI-H\u5be6\u9ad4\u7624\u7684\u7642\u6548\u548c\u5b89\u5168\u6027\u3002 \u4e8c\u3001\u7814\u7a76\u8a2d\u8a08\u548c\u65b9\u6cd5 \u672c\u7814\u7a76\u70ba\u55ae\u81c2\u3001II\u671f\u95dc\u9375\u81e8\u5e8a\u7814\u7a76\uff0c\u7d0d\u5165\u4e0d\u53ef\u5207\u9664\u6216\u8f49\u79fb\u6027\u7d93\u7d44\u7e54\u75c5\u7406\u5b78\u6216\u7d30\u80de\u5b78\u78ba\u8a8d\u7684dMMR\/MSI-H\u5be6\u9ad4\u7624\u60a3\u8005\uff0c\u63a5\u53d7\u827e\u5e15\u6d1b\u5229\u55ae\u6297\u55ae\u85e5\u6cbb\u7642\uff0c\u7d66\u85e5\u65b9\u6848\u70ba200 mg\u56fa\u5b9a\u5291\u91cf\uff08\u5982\u679c\u53d7\u8a66\u8005\u9ad4\u91cd\uff1c40 kg\uff0c\u7d66\u85e5\u5291\u91cf\u70ba3 mg\/kg\uff09\uff0c\u975c\u8108\u6ef4\u6ce8\uff0c\u6bcf3\u5468\u7d66\u85e51\u6b21\u3002\u60a3\u8005\u63a5\u53d7\u827e\u5e15\u6d1b\u5229\u55ae\u6297\u6cbb\u7642\u76f4\u81f3\u75be\u75c5\u9032\u5c55\u3001\u51fa\u73fe\u4e0d\u53ef\u8010\u53d7\u7684\u6bd2\u6027\u3001\u958b\u59cb\u65b0\u7684\u6297\u816b\u7624\u6cbb\u7642\u3001\u6b7b\u4ea1\u3001\u64a4\u56de\u77e5\u60c5\u540c\u610f\u7b49\u539f\u56e0\uff0c\u6700\u9577\u6cbb\u7642\u6642\u9593\u4e0d\u8d85\u904e2\u5e74\u3002\u6cbb\u7642\u7d50\u675f\u5f8c\uff0c\u5c0d\u60a3\u8005\u9032\u884c\u751f\u5b58\u96a8\u8a2a\u3002\u7814\u7a76\u7684\u4e3b\u8981\u7d42\u9ede\u70baIRRC\u6839\u64da\u5be6\u9ad4\u816b\u7624\u7642\u6548\u8a55\u50f9\u6a19\u6e96\uff081.1\u7248\uff09\u8a55\u4f30\u7684ORR\u3002\u7814\u7a76\u8a2d\u8a08\u5982\u4e0b\u5716\u6240\u793a\u3002 \u4e09\u3001\u7814\u7a76\u7d50\u679c \u5f9e2020\u5e746\u6708\u81f32023\u5e741\u6708\uff0c\u7814\u7a76\u5171\u7d0d\u5165120\u4f8bdMMR\/MSI-H\u5be6\u9ad4\u7624\u60a3\u8005\uff0c\u5176\u4e2d\u7d50\u76f4\u8178\u764c\u60a3\u800580\u4f8b\uff0866.7%\uff09\uff0c\u80c3\u764c\u60a3\u800518\u4f8b\uff0815.0%\uff09\uff0c\u5176\u5b83\u5be6\u9ad4\u7624\u60a3\u800522\u4f8b\uff0818.3%\uff09\uff1b97.5%\u7684\u60a3\u8005\u5728\u5165\u7d44\u6642\u75be\u75c5\u5206\u671f\u70baIV\u671f\uff0c\u4e2d\u4f4d\u6cbb\u7642\u7dda\u6578\u70ba2.0\uff08\u7bc4\u570d\uff0c0\u20136\uff09\u3002 \u5728\u7642\u6548\u65b9\u9762\uff0c\u622a\u81f32023\u5e747\u670820\u65e5\uff0c\u4e2d\u4f4d\u96a8\u8a2a\u6642\u9593\u70ba13.6\u500b\u6708\uff0c\u670911\u4f8b\u60a3\u8005\u9054\u5230\u5b8c\u5168\u7de9\u89e3\uff08CR\uff09\uff0c44\u4f8b\u60a3\u8005\u9054\u5230\u90e8\u5206\u7de9\u89e3\uff08PR\uff09\uff0cORR\u70ba45.8%\uff0895% CI: 36.7%\u201355.2%\uff09\uff0c\u75be\u75c5\u63a7\u5236\u7387\uff08DCR\uff09\u70ba77.5%\uff0895% CI: 69.0%\u201384.6%\uff09\u3002\u5728\u7d50\u76f4\u8178\u764c\u60a3\u8005\u4e2d\uff0cORR\u548cDCR\u5206\u5225\u70ba42.5%\uff0895% CI: 31.5%\u201354.1%\uff09\u548c77.5%\uff0895% CI: 31.5%\u201354.1%\uff09\u3002\u4e2d\u4f4d\u7de9\u89e3\u6301\u7e8c\u6642\u9593\uff08DoR\uff09\u5c1a\u672a\u9054\u5230\uff0c6\u500b\u6708\u548c12\u500b\u6708DoR\u7387\u5206\u5225\u70ba100%\u548c97.4%\uff1b\u4e2d\u4f4d\u7121\u9032\u5c55\u751f\u5b58\u671f\uff08PFS\uff09\u548c\u4e2d\u4f4d\u7e3d\u751f\u5b58\u671f\uff08OS\uff09\u672a\u9054\u5230\u3002\u7de9\u89e3\u60a3\u8005\u7684\u9776\u75c5\u7076\u6700\u4f73\u8b8a\u5316\u60c5\u6cc1\u5982\u4e0b\u5716\u6240\u793a\u3002 \u56db\u3001\u5c0f\u7d50 \u827e\u5e15\u6d1b\u5229\u55ae\u6297\u55ae\u85e5\u6cbb\u7642\u4e0d\u53ef\u5207\u9664\u6216\u8f49\u79fb\u6027dMMR\/MSI-H\u5be6\u9ad4\u7624\u5177\u6709\u826f\u597d\u7684\u7642\u6548\u548c\u5b89\u5168\u6027\u3002\u9f4a\u9b6f\u88fd\u85e5\u827e\u5e15\u6d1b\u5229\u55ae\u6297\u4e0a\u5e02\u7533\u8acb\u5df2\u65bc\u4eca\u5e749\u6708\u7372\u5f97CDE\u53d7\u7406\u3002   \u53c3\u8003\u6587\u737b\uff1a   1. Bhamidipati D, Subbiah V. Tumor-agnostic drug development in dMMR\/MSI-H solid tumors. Trends Cancer. 2023;9(10):828-839.   2. Le DT, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.   3. Li J, et al. Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair\/microsatellite instability high solid tumors. J Hematol Oncol. 2021;14(1):95.   4. Huang Z, et al. A first-in-human, open-label, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, pharmacokinetics\/pharmacodynamics, and antitumor activity of QL1604, a humanized anti-PD-1 mAb, in patients with advanced or metastatic solid tumors. Front Immunol. 2023;14:1258573.    \u00a0\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pingtungtimes.com.tw\/?p=202833\" \/>\n<meta property=\"og:site_name\" content=\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/pingtungnews\" \/>\n<meta property=\"article:published_time\" content=\"2023-12-06T08:47:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/12\/QILU_logo.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"400\" \/>\n\t<meta property=\"og:image:height\" content=\"142\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"\u7f8e\u901a\u793e\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u4f5c\u8005:\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u7f8e\u901a\u793e\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u9810\u4f30\u95b1\u8b80\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 \u5206\u9418\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=202833#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=202833\"},\"author\":{\"name\":\"\u7f8e\u901a\u793e\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#\\\/schema\\\/person\\\/683b937f29ec1537972f6c41e22a2cf3\"},\"headline\":\"\u5ba2\u89c0\u7de9\u89e3\u7387\u905445.8%\uff0c\u9f4a\u9b6f\u88fd\u85e5\u827e\u5e15\u6d1b\u5229\u55ae\u6297\u55ae\u85e5\u6cbb\u7642\u665a\u671f\u5be6\u9ad4\u7624II\u671f\u7814\u7a76\u7d50\u679c\u5728ESMO\u4e9e\u6d32\u5e74\u6703\u516c\u4f48\",\"datePublished\":\"2023-12-06T08:47:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=202833\"},\"wordCount\":162,\"publisher\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=202833#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/QILU_logo.jpg\",\"articleSection\":[\"\u7f8e\u901a\u793e\"],\"inLanguage\":\"zh-TW\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=202833\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=202833\",\"name\":\"\u5ba2\u89c0\u7de9\u89e3\u7387\u905445.8%\uff0c\u9f4a\u9b6f\u88fd\u85e5\u827e\u5e15\u6d1b\u5229\u55ae\u6297\u55ae\u85e5\u6cbb\u7642\u665a\u671f\u5be6\u9ad4\u7624II\u671f\u7814\u7a76\u7d50\u679c\u5728ESMO\u4e9e\u6d32\u5e74\u6703\u516c\u4f48 - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=202833#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=202833#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/QILU_logo.jpg\",\"datePublished\":\"2023-12-06T08:47:00+00:00\",\"description\":\"\u6fdf\u53572023\u5e7412\u67086\u65e5 \\\/\u7f8e\u901a\u793e\\\/ -- 12\u67081\u81f33\u65e5\uff0c\u57282023\u5e74\u6b50\u6d32\u816b\u7624\u5167\u79d1\u5b78\u6703\u4e9e\u6d32\u5e74\u6703\uff08ESMO Asia\uff09\u4e0a\uff0c\u9f4a\u9b6f\u88fd\u85e5\u4ee5\u58c1\u5831\u5f62\u5f0f\u5831\u544a\u4e861\u985e\u65b0\u85e5\u827e\u5e15\u6d1b\u5229\u55ae\u6297\uff08QL1604\uff09\u55ae\u85e5\u6cbb\u7642\u4e0d\u53ef\u5207\u9664\u6216\u8f49\u79fb\u6027dMMR\\\/MSI-H\u5be6\u9ad4\u7624\u7684\u55ae\u81c2\u3001II\u671f\u95dc\u9375\u81e8\u5e8a\u7814\u7a76\u6700\u65b0\u7d50\u679c\u3002\u4e3b\u8981\u7814\u7a76\u8005\u70ba\u5fa9\u65e6\u5927\u5b78\u9644\u5c6c\u816b\u7624\u91ab\u9662\u90ed\u5049\u528d\u6559\u6388\u548c\u56db\u5ddd\u5927\u5b78\u83ef\u897f\u91ab\u9662\u7562\u92d2\u6559\u6388\u3002 \u827e\u5e15\u6d1b\u5229\u55ae\u6297\u662f\u4e00\u7a2e\u8207PD-1\u7d50\u5408\u7684\u9ad8\u9078\u64c7\u6027\u4eba\u6e90\u5316\u55ae\u514b\u9686\u6297\u9ad4\u3002\u7814\u7a76\u7d50\u679c\u986f\u793a\uff0c\u827e\u5e15\u6d1b\u5229\u55ae\u6297\u55ae\u85e5\u6cbb\u7642\u4e0d\u53ef\u5207\u9664\u6216\u8f49\u79fb\u6027dMMR\\\/MSI-H\u5be6\u9ad4\u7624\u5177\u6709\u826f\u597d\u7684\u7642\u6548\uff0c\u7368\u7acb\u5f71\u50cf\u8a55\u4f30\u59d4\u54e1\u6703\uff08IRRC\uff09\u8a55\u4f30\u7684\u5168\u4eba\u7fa4\u5ba2\u89c0\u7de9\u89e3\u7387\uff08ORR\uff09\u70ba45.8% (95%CI\uff0c 36.7-55.2)\uff0c\u8d85\u904e\u9810\u8a2d\u4e3b\u8981\u7814\u7a76\u7d42\u9ede\u3002 \u4e00\u3001\u7814\u7a76\u80cc\u666f DNA\u932f\u914d\u4fee\u5fa9\u7f3a\u9677\uff08dMMR\uff09\u6216\u9ad8\u5ea6\u5fae\u885b\u661f\u4e0d\u7a69\u5b9a\uff08MSI-H\uff09\u662f\u5be6\u9ad4\u7624\u7684\u7368\u7279\u8868\u578b\u3002DNA\u8907\u88fd\u904e\u7a0b\u4e2d\uff0c\u5fae\u885b\u661f\u5e8f\u5217\u6700\u6613\u767c\u751f\u932f\u914d\uff0c\u9700\u8981\u9032\u884c\u932f\u914d\u4fee\u5fa9\uff0cdMMR\u53ef\u5c0e\u81f4\u79fb\u78bc\u7a81\u8b8a\uff0c\u5f15\u8d77\u5fae\u885b\u661f\u4e0d\u7a69\u5b9a\uff08MSI\uff09\u3002dMMR\\\/MSI-H\u5be6\u9ad4\u7624\u5c0d\u514d\u75ab\u6aa2\u67e5\u9ede\u6291\u5236\u5291\u6cbb\u7642\u53cd\u61c9\u826f\u597d\uff0c\u7a0b\u5e8f\u6027\u6b7b\u4ea1\u53d7\u9ad4-1\uff08PD-1\uff09\u6216\u7a0b\u5e8f\u6027\u6b7b\u4ea1\u914d\u9ad4-1\uff08PD-L1\uff09\u6291\u5236\u5291\u6cbb\u7642dMMR\\\/MSI-H\u5be6\u9ad4\u7624\u5177\u6709\u8f03\u9ad8\u7684\u5ba2\u89c0\u7de9\u89e3\u7387\uff08ORR\uff09\uff0c\u4e26\u4e14\u7de9\u89e3\u6301\u7e8c\u6642\u9593\u9577\u3002 \u827e\u5e15\u6d1b\u5229\u55ae\u6297\u6cbb\u7642\u665a\u671f\u5be6\u9ad4\u7624\u7684I\u671f\u7814\u7a76\u8868\u73fe\u51fa\u826f\u597d\u7684\u5b89\u5168\u6027\u548c\u6297\u816b\u7624\u6d3b\u6027\uff0c\u5728\u63a5\u53d7\u827e\u5e15\u6d1b\u5229\u55ae\u62970.3-3 mg\\\/kg Q3W\u7684\u6240\u6709\u60a3\u8005\u4e2d\uff0cORR\u9054\u523020%\u3002\u672c\u95dc\u9375\u7814\u7a76\u65e8\u5728\u8a55\u4f30\u827e\u5e15\u6d1b\u5229\u55ae\u6297\u55ae\u85e5\u6cbb\u7642\u4e0d\u53ef\u5207\u9664\u6216\u8f49\u79fb\u6027dMMR\\\/MSI-H\u5be6\u9ad4\u7624\u7684\u7642\u6548\u548c\u5b89\u5168\u6027\u3002 \u4e8c\u3001\u7814\u7a76\u8a2d\u8a08\u548c\u65b9\u6cd5 \u672c\u7814\u7a76\u70ba\u55ae\u81c2\u3001II\u671f\u95dc\u9375\u81e8\u5e8a\u7814\u7a76\uff0c\u7d0d\u5165\u4e0d\u53ef\u5207\u9664\u6216\u8f49\u79fb\u6027\u7d93\u7d44\u7e54\u75c5\u7406\u5b78\u6216\u7d30\u80de\u5b78\u78ba\u8a8d\u7684dMMR\\\/MSI-H\u5be6\u9ad4\u7624\u60a3\u8005\uff0c\u63a5\u53d7\u827e\u5e15\u6d1b\u5229\u55ae\u6297\u55ae\u85e5\u6cbb\u7642\uff0c\u7d66\u85e5\u65b9\u6848\u70ba200 mg\u56fa\u5b9a\u5291\u91cf\uff08\u5982\u679c\u53d7\u8a66\u8005\u9ad4\u91cd\uff1c40 kg\uff0c\u7d66\u85e5\u5291\u91cf\u70ba3 mg\\\/kg\uff09\uff0c\u975c\u8108\u6ef4\u6ce8\uff0c\u6bcf3\u5468\u7d66\u85e51\u6b21\u3002\u60a3\u8005\u63a5\u53d7\u827e\u5e15\u6d1b\u5229\u55ae\u6297\u6cbb\u7642\u76f4\u81f3\u75be\u75c5\u9032\u5c55\u3001\u51fa\u73fe\u4e0d\u53ef\u8010\u53d7\u7684\u6bd2\u6027\u3001\u958b\u59cb\u65b0\u7684\u6297\u816b\u7624\u6cbb\u7642\u3001\u6b7b\u4ea1\u3001\u64a4\u56de\u77e5\u60c5\u540c\u610f\u7b49\u539f\u56e0\uff0c\u6700\u9577\u6cbb\u7642\u6642\u9593\u4e0d\u8d85\u904e2\u5e74\u3002\u6cbb\u7642\u7d50\u675f\u5f8c\uff0c\u5c0d\u60a3\u8005\u9032\u884c\u751f\u5b58\u96a8\u8a2a\u3002\u7814\u7a76\u7684\u4e3b\u8981\u7d42\u9ede\u70baIRRC\u6839\u64da\u5be6\u9ad4\u816b\u7624\u7642\u6548\u8a55\u50f9\u6a19\u6e96\uff081.1\u7248\uff09\u8a55\u4f30\u7684ORR\u3002\u7814\u7a76\u8a2d\u8a08\u5982\u4e0b\u5716\u6240\u793a\u3002 \u4e09\u3001\u7814\u7a76\u7d50\u679c \u5f9e2020\u5e746\u6708\u81f32023\u5e741\u6708\uff0c\u7814\u7a76\u5171\u7d0d\u5165120\u4f8bdMMR\\\/MSI-H\u5be6\u9ad4\u7624\u60a3\u8005\uff0c\u5176\u4e2d\u7d50\u76f4\u8178\u764c\u60a3\u800580\u4f8b\uff0866.7%\uff09\uff0c\u80c3\u764c\u60a3\u800518\u4f8b\uff0815.0%\uff09\uff0c\u5176\u5b83\u5be6\u9ad4\u7624\u60a3\u800522\u4f8b\uff0818.3%\uff09\uff1b97.5%\u7684\u60a3\u8005\u5728\u5165\u7d44\u6642\u75be\u75c5\u5206\u671f\u70baIV\u671f\uff0c\u4e2d\u4f4d\u6cbb\u7642\u7dda\u6578\u70ba2.0\uff08\u7bc4\u570d\uff0c0\u20136\uff09\u3002 \u5728\u7642\u6548\u65b9\u9762\uff0c\u622a\u81f32023\u5e747\u670820\u65e5\uff0c\u4e2d\u4f4d\u96a8\u8a2a\u6642\u9593\u70ba13.6\u500b\u6708\uff0c\u670911\u4f8b\u60a3\u8005\u9054\u5230\u5b8c\u5168\u7de9\u89e3\uff08CR\uff09\uff0c44\u4f8b\u60a3\u8005\u9054\u5230\u90e8\u5206\u7de9\u89e3\uff08PR\uff09\uff0cORR\u70ba45.8%\uff0895% CI: 36.7%\u201355.2%\uff09\uff0c\u75be\u75c5\u63a7\u5236\u7387\uff08DCR\uff09\u70ba77.5%\uff0895% CI: 69.0%\u201384.6%\uff09\u3002\u5728\u7d50\u76f4\u8178\u764c\u60a3\u8005\u4e2d\uff0cORR\u548cDCR\u5206\u5225\u70ba42.5%\uff0895% CI: 31.5%\u201354.1%\uff09\u548c77.5%\uff0895% CI: 31.5%\u201354.1%\uff09\u3002\u4e2d\u4f4d\u7de9\u89e3\u6301\u7e8c\u6642\u9593\uff08DoR\uff09\u5c1a\u672a\u9054\u5230\uff0c6\u500b\u6708\u548c12\u500b\u6708DoR\u7387\u5206\u5225\u70ba100%\u548c97.4%\uff1b\u4e2d\u4f4d\u7121\u9032\u5c55\u751f\u5b58\u671f\uff08PFS\uff09\u548c\u4e2d\u4f4d\u7e3d\u751f\u5b58\u671f\uff08OS\uff09\u672a\u9054\u5230\u3002\u7de9\u89e3\u60a3\u8005\u7684\u9776\u75c5\u7076\u6700\u4f73\u8b8a\u5316\u60c5\u6cc1\u5982\u4e0b\u5716\u6240\u793a\u3002 \u56db\u3001\u5c0f\u7d50 \u827e\u5e15\u6d1b\u5229\u55ae\u6297\u55ae\u85e5\u6cbb\u7642\u4e0d\u53ef\u5207\u9664\u6216\u8f49\u79fb\u6027dMMR\\\/MSI-H\u5be6\u9ad4\u7624\u5177\u6709\u826f\u597d\u7684\u7642\u6548\u548c\u5b89\u5168\u6027\u3002\u9f4a\u9b6f\u88fd\u85e5\u827e\u5e15\u6d1b\u5229\u55ae\u6297\u4e0a\u5e02\u7533\u8acb\u5df2\u65bc\u4eca\u5e749\u6708\u7372\u5f97CDE\u53d7\u7406\u3002 \u53c3\u8003\u6587\u737b\uff1a 1. Bhamidipati D, Subbiah V. Tumor-agnostic drug development in dMMR\\\/MSI-H solid tumors. Trends Cancer. 2023;9(10):828-839. 2. Le DT, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20. 3. Li J, et al. Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair\\\/microsatellite instability high solid tumors. J Hematol Oncol. 2021;14(1):95. 4. Huang Z, et al. A first-in-human, open-label, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, pharmacokinetics\\\/pharmacodynamics, and antitumor activity of QL1604, a humanized anti-PD-1 mAb, in patients with advanced or metastatic solid tumors. Front Immunol. 2023;14:1258573. \u00a0\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=202833#breadcrumb\"},\"inLanguage\":\"zh-TW\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=202833\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-TW\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=202833#primaryimage\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/QILU_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/QILU_logo.jpg\",\"width\":400,\"height\":142},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=202833#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"\u9996\u9801\",\"item\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u5ba2\u89c0\u7de9\u89e3\u7387\u905445.8%\uff0c\u9f4a\u9b6f\u88fd\u85e5\u827e\u5e15\u6d1b\u5229\u55ae\u6297\u55ae\u85e5\u6cbb\u7642\u665a\u671f\u5be6\u9ad4\u7624II\u671f\u7814\u7a76\u7d50\u679c\u5728ESMO\u4e9e\u6d32\u5e74\u6703\u516c\u4f48\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#website\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/\",\"name\":\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\",\"description\":\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831PingtungTimes\uff0c\u6700\u95dc\u5fc3\u5728\u5730\u7684\u5a92\u9ad4\",\"publisher\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"zh-TW\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#organization\",\"name\":\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-TW\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo-150.png\",\"contentUrl\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo-150.png\",\"width\":150,\"height\":150,\"caption\":\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\"},\"image\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/pingtungnews\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#\\\/schema\\\/person\\\/683b937f29ec1537972f6c41e22a2cf3\",\"name\":\"\u7f8e\u901a\u793e\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-TW\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g\",\"caption\":\"\u7f8e\u901a\u793e\"},\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?author=16\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u5ba2\u89c0\u7de9\u89e3\u7387\u905445.8%\uff0c\u9f4a\u9b6f\u88fd\u85e5\u827e\u5e15\u6d1b\u5229\u55ae\u6297\u55ae\u85e5\u6cbb\u7642\u665a\u671f\u5be6\u9ad4\u7624II\u671f\u7814\u7a76\u7d50\u679c\u5728ESMO\u4e9e\u6d32\u5e74\u6703\u516c\u4f48 - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","description":"\u6fdf\u53572023\u5e7412\u67086\u65e5 \/\u7f8e\u901a\u793e\/ -- 12\u67081\u81f33\u65e5\uff0c\u57282023\u5e74\u6b50\u6d32\u816b\u7624\u5167\u79d1\u5b78\u6703\u4e9e\u6d32\u5e74\u6703\uff08ESMO Asia\uff09\u4e0a\uff0c\u9f4a\u9b6f\u88fd\u85e5\u4ee5\u58c1\u5831\u5f62\u5f0f\u5831\u544a\u4e861\u985e\u65b0\u85e5\u827e\u5e15\u6d1b\u5229\u55ae\u6297\uff08QL1604\uff09\u55ae\u85e5\u6cbb\u7642\u4e0d\u53ef\u5207\u9664\u6216\u8f49\u79fb\u6027dMMR\/MSI-H\u5be6\u9ad4\u7624\u7684\u55ae\u81c2\u3001II\u671f\u95dc\u9375\u81e8\u5e8a\u7814\u7a76\u6700\u65b0\u7d50\u679c\u3002\u4e3b\u8981\u7814\u7a76\u8005\u70ba\u5fa9\u65e6\u5927\u5b78\u9644\u5c6c\u816b\u7624\u91ab\u9662\u90ed\u5049\u528d\u6559\u6388\u548c\u56db\u5ddd\u5927\u5b78\u83ef\u897f\u91ab\u9662\u7562\u92d2\u6559\u6388\u3002     \u827e\u5e15\u6d1b\u5229\u55ae\u6297\u662f\u4e00\u7a2e\u8207PD-1\u7d50\u5408\u7684\u9ad8\u9078\u64c7\u6027\u4eba\u6e90\u5316\u55ae\u514b\u9686\u6297\u9ad4\u3002\u7814\u7a76\u7d50\u679c\u986f\u793a\uff0c\u827e\u5e15\u6d1b\u5229\u55ae\u6297\u55ae\u85e5\u6cbb\u7642\u4e0d\u53ef\u5207\u9664\u6216\u8f49\u79fb\u6027dMMR\/MSI-H\u5be6\u9ad4\u7624\u5177\u6709\u826f\u597d\u7684\u7642\u6548\uff0c\u7368\u7acb\u5f71\u50cf\u8a55\u4f30\u59d4\u54e1\u6703\uff08IRRC\uff09\u8a55\u4f30\u7684\u5168\u4eba\u7fa4\u5ba2\u89c0\u7de9\u89e3\u7387\uff08ORR\uff09\u70ba45.8% (95%CI\uff0c 36.7-55.2)\uff0c\u8d85\u904e\u9810\u8a2d\u4e3b\u8981\u7814\u7a76\u7d42\u9ede\u3002 \u4e00\u3001\u7814\u7a76\u80cc\u666f DNA\u932f\u914d\u4fee\u5fa9\u7f3a\u9677\uff08dMMR\uff09\u6216\u9ad8\u5ea6\u5fae\u885b\u661f\u4e0d\u7a69\u5b9a\uff08MSI-H\uff09\u662f\u5be6\u9ad4\u7624\u7684\u7368\u7279\u8868\u578b\u3002DNA\u8907\u88fd\u904e\u7a0b\u4e2d\uff0c\u5fae\u885b\u661f\u5e8f\u5217\u6700\u6613\u767c\u751f\u932f\u914d\uff0c\u9700\u8981\u9032\u884c\u932f\u914d\u4fee\u5fa9\uff0cdMMR\u53ef\u5c0e\u81f4\u79fb\u78bc\u7a81\u8b8a\uff0c\u5f15\u8d77\u5fae\u885b\u661f\u4e0d\u7a69\u5b9a\uff08MSI\uff09\u3002dMMR\/MSI-H\u5be6\u9ad4\u7624\u5c0d\u514d\u75ab\u6aa2\u67e5\u9ede\u6291\u5236\u5291\u6cbb\u7642\u53cd\u61c9\u826f\u597d\uff0c\u7a0b\u5e8f\u6027\u6b7b\u4ea1\u53d7\u9ad4-1\uff08PD-1\uff09\u6216\u7a0b\u5e8f\u6027\u6b7b\u4ea1\u914d\u9ad4-1\uff08PD-L1\uff09\u6291\u5236\u5291\u6cbb\u7642dMMR\/MSI-H\u5be6\u9ad4\u7624\u5177\u6709\u8f03\u9ad8\u7684\u5ba2\u89c0\u7de9\u89e3\u7387\uff08ORR\uff09\uff0c\u4e26\u4e14\u7de9\u89e3\u6301\u7e8c\u6642\u9593\u9577\u3002 \u827e\u5e15\u6d1b\u5229\u55ae\u6297\u6cbb\u7642\u665a\u671f\u5be6\u9ad4\u7624\u7684I\u671f\u7814\u7a76\u8868\u73fe\u51fa\u826f\u597d\u7684\u5b89\u5168\u6027\u548c\u6297\u816b\u7624\u6d3b\u6027\uff0c\u5728\u63a5\u53d7\u827e\u5e15\u6d1b\u5229\u55ae\u62970.3-3 mg\/kg Q3W\u7684\u6240\u6709\u60a3\u8005\u4e2d\uff0cORR\u9054\u523020%\u3002\u672c\u95dc\u9375\u7814\u7a76\u65e8\u5728\u8a55\u4f30\u827e\u5e15\u6d1b\u5229\u55ae\u6297\u55ae\u85e5\u6cbb\u7642\u4e0d\u53ef\u5207\u9664\u6216\u8f49\u79fb\u6027dMMR\/MSI-H\u5be6\u9ad4\u7624\u7684\u7642\u6548\u548c\u5b89\u5168\u6027\u3002 \u4e8c\u3001\u7814\u7a76\u8a2d\u8a08\u548c\u65b9\u6cd5 \u672c\u7814\u7a76\u70ba\u55ae\u81c2\u3001II\u671f\u95dc\u9375\u81e8\u5e8a\u7814\u7a76\uff0c\u7d0d\u5165\u4e0d\u53ef\u5207\u9664\u6216\u8f49\u79fb\u6027\u7d93\u7d44\u7e54\u75c5\u7406\u5b78\u6216\u7d30\u80de\u5b78\u78ba\u8a8d\u7684dMMR\/MSI-H\u5be6\u9ad4\u7624\u60a3\u8005\uff0c\u63a5\u53d7\u827e\u5e15\u6d1b\u5229\u55ae\u6297\u55ae\u85e5\u6cbb\u7642\uff0c\u7d66\u85e5\u65b9\u6848\u70ba200 mg\u56fa\u5b9a\u5291\u91cf\uff08\u5982\u679c\u53d7\u8a66\u8005\u9ad4\u91cd\uff1c40 kg\uff0c\u7d66\u85e5\u5291\u91cf\u70ba3 mg\/kg\uff09\uff0c\u975c\u8108\u6ef4\u6ce8\uff0c\u6bcf3\u5468\u7d66\u85e51\u6b21\u3002\u60a3\u8005\u63a5\u53d7\u827e\u5e15\u6d1b\u5229\u55ae\u6297\u6cbb\u7642\u76f4\u81f3\u75be\u75c5\u9032\u5c55\u3001\u51fa\u73fe\u4e0d\u53ef\u8010\u53d7\u7684\u6bd2\u6027\u3001\u958b\u59cb\u65b0\u7684\u6297\u816b\u7624\u6cbb\u7642\u3001\u6b7b\u4ea1\u3001\u64a4\u56de\u77e5\u60c5\u540c\u610f\u7b49\u539f\u56e0\uff0c\u6700\u9577\u6cbb\u7642\u6642\u9593\u4e0d\u8d85\u904e2\u5e74\u3002\u6cbb\u7642\u7d50\u675f\u5f8c\uff0c\u5c0d\u60a3\u8005\u9032\u884c\u751f\u5b58\u96a8\u8a2a\u3002\u7814\u7a76\u7684\u4e3b\u8981\u7d42\u9ede\u70baIRRC\u6839\u64da\u5be6\u9ad4\u816b\u7624\u7642\u6548\u8a55\u50f9\u6a19\u6e96\uff081.1\u7248\uff09\u8a55\u4f30\u7684ORR\u3002\u7814\u7a76\u8a2d\u8a08\u5982\u4e0b\u5716\u6240\u793a\u3002 \u4e09\u3001\u7814\u7a76\u7d50\u679c \u5f9e2020\u5e746\u6708\u81f32023\u5e741\u6708\uff0c\u7814\u7a76\u5171\u7d0d\u5165120\u4f8bdMMR\/MSI-H\u5be6\u9ad4\u7624\u60a3\u8005\uff0c\u5176\u4e2d\u7d50\u76f4\u8178\u764c\u60a3\u800580\u4f8b\uff0866.7%\uff09\uff0c\u80c3\u764c\u60a3\u800518\u4f8b\uff0815.0%\uff09\uff0c\u5176\u5b83\u5be6\u9ad4\u7624\u60a3\u800522\u4f8b\uff0818.3%\uff09\uff1b97.5%\u7684\u60a3\u8005\u5728\u5165\u7d44\u6642\u75be\u75c5\u5206\u671f\u70baIV\u671f\uff0c\u4e2d\u4f4d\u6cbb\u7642\u7dda\u6578\u70ba2.0\uff08\u7bc4\u570d\uff0c0\u20136\uff09\u3002 \u5728\u7642\u6548\u65b9\u9762\uff0c\u622a\u81f32023\u5e747\u670820\u65e5\uff0c\u4e2d\u4f4d\u96a8\u8a2a\u6642\u9593\u70ba13.6\u500b\u6708\uff0c\u670911\u4f8b\u60a3\u8005\u9054\u5230\u5b8c\u5168\u7de9\u89e3\uff08CR\uff09\uff0c44\u4f8b\u60a3\u8005\u9054\u5230\u90e8\u5206\u7de9\u89e3\uff08PR\uff09\uff0cORR\u70ba45.8%\uff0895% CI: 36.7%\u201355.2%\uff09\uff0c\u75be\u75c5\u63a7\u5236\u7387\uff08DCR\uff09\u70ba77.5%\uff0895% CI: 69.0%\u201384.6%\uff09\u3002\u5728\u7d50\u76f4\u8178\u764c\u60a3\u8005\u4e2d\uff0cORR\u548cDCR\u5206\u5225\u70ba42.5%\uff0895% CI: 31.5%\u201354.1%\uff09\u548c77.5%\uff0895% CI: 31.5%\u201354.1%\uff09\u3002\u4e2d\u4f4d\u7de9\u89e3\u6301\u7e8c\u6642\u9593\uff08DoR\uff09\u5c1a\u672a\u9054\u5230\uff0c6\u500b\u6708\u548c12\u500b\u6708DoR\u7387\u5206\u5225\u70ba100%\u548c97.4%\uff1b\u4e2d\u4f4d\u7121\u9032\u5c55\u751f\u5b58\u671f\uff08PFS\uff09\u548c\u4e2d\u4f4d\u7e3d\u751f\u5b58\u671f\uff08OS\uff09\u672a\u9054\u5230\u3002\u7de9\u89e3\u60a3\u8005\u7684\u9776\u75c5\u7076\u6700\u4f73\u8b8a\u5316\u60c5\u6cc1\u5982\u4e0b\u5716\u6240\u793a\u3002 \u56db\u3001\u5c0f\u7d50 \u827e\u5e15\u6d1b\u5229\u55ae\u6297\u55ae\u85e5\u6cbb\u7642\u4e0d\u53ef\u5207\u9664\u6216\u8f49\u79fb\u6027dMMR\/MSI-H\u5be6\u9ad4\u7624\u5177\u6709\u826f\u597d\u7684\u7642\u6548\u548c\u5b89\u5168\u6027\u3002\u9f4a\u9b6f\u88fd\u85e5\u827e\u5e15\u6d1b\u5229\u55ae\u6297\u4e0a\u5e02\u7533\u8acb\u5df2\u65bc\u4eca\u5e749\u6708\u7372\u5f97CDE\u53d7\u7406\u3002   \u53c3\u8003\u6587\u737b\uff1a   1. Bhamidipati D, Subbiah V. Tumor-agnostic drug development in dMMR\/MSI-H solid tumors. Trends Cancer. 2023;9(10):828-839.   2. Le DT, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.   3. Li J, et al. Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair\/microsatellite instability high solid tumors. J Hematol Oncol. 2021;14(1):95.   4. Huang Z, et al. A first-in-human, open-label, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, pharmacokinetics\/pharmacodynamics, and antitumor activity of QL1604, a humanized anti-PD-1 mAb, in patients with advanced or metastatic solid tumors. Front Immunol. 2023;14:1258573.    \u00a0","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pingtungtimes.com.tw\/?p=202833","og_locale":"zh_TW","og_type":"article","og_title":"\u5ba2\u89c0\u7de9\u89e3\u7387\u905445.8%\uff0c\u9f4a\u9b6f\u88fd\u85e5\u827e\u5e15\u6d1b\u5229\u55ae\u6297\u55ae\u85e5\u6cbb\u7642\u665a\u671f\u5be6\u9ad4\u7624II\u671f\u7814\u7a76\u7d50\u679c\u5728ESMO\u4e9e\u6d32\u5e74\u6703\u516c\u4f48 - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","og_description":"\u6fdf\u53572023\u5e7412\u67086\u65e5 \/\u7f8e\u901a\u793e\/ -- 12\u67081\u81f33\u65e5\uff0c\u57282023\u5e74\u6b50\u6d32\u816b\u7624\u5167\u79d1\u5b78\u6703\u4e9e\u6d32\u5e74\u6703\uff08ESMO Asia\uff09\u4e0a\uff0c\u9f4a\u9b6f\u88fd\u85e5\u4ee5\u58c1\u5831\u5f62\u5f0f\u5831\u544a\u4e861\u985e\u65b0\u85e5\u827e\u5e15\u6d1b\u5229\u55ae\u6297\uff08QL1604\uff09\u55ae\u85e5\u6cbb\u7642\u4e0d\u53ef\u5207\u9664\u6216\u8f49\u79fb\u6027dMMR\/MSI-H\u5be6\u9ad4\u7624\u7684\u55ae\u81c2\u3001II\u671f\u95dc\u9375\u81e8\u5e8a\u7814\u7a76\u6700\u65b0\u7d50\u679c\u3002\u4e3b\u8981\u7814\u7a76\u8005\u70ba\u5fa9\u65e6\u5927\u5b78\u9644\u5c6c\u816b\u7624\u91ab\u9662\u90ed\u5049\u528d\u6559\u6388\u548c\u56db\u5ddd\u5927\u5b78\u83ef\u897f\u91ab\u9662\u7562\u92d2\u6559\u6388\u3002     \u827e\u5e15\u6d1b\u5229\u55ae\u6297\u662f\u4e00\u7a2e\u8207PD-1\u7d50\u5408\u7684\u9ad8\u9078\u64c7\u6027\u4eba\u6e90\u5316\u55ae\u514b\u9686\u6297\u9ad4\u3002\u7814\u7a76\u7d50\u679c\u986f\u793a\uff0c\u827e\u5e15\u6d1b\u5229\u55ae\u6297\u55ae\u85e5\u6cbb\u7642\u4e0d\u53ef\u5207\u9664\u6216\u8f49\u79fb\u6027dMMR\/MSI-H\u5be6\u9ad4\u7624\u5177\u6709\u826f\u597d\u7684\u7642\u6548\uff0c\u7368\u7acb\u5f71\u50cf\u8a55\u4f30\u59d4\u54e1\u6703\uff08IRRC\uff09\u8a55\u4f30\u7684\u5168\u4eba\u7fa4\u5ba2\u89c0\u7de9\u89e3\u7387\uff08ORR\uff09\u70ba45.8% (95%CI\uff0c 36.7-55.2)\uff0c\u8d85\u904e\u9810\u8a2d\u4e3b\u8981\u7814\u7a76\u7d42\u9ede\u3002 \u4e00\u3001\u7814\u7a76\u80cc\u666f DNA\u932f\u914d\u4fee\u5fa9\u7f3a\u9677\uff08dMMR\uff09\u6216\u9ad8\u5ea6\u5fae\u885b\u661f\u4e0d\u7a69\u5b9a\uff08MSI-H\uff09\u662f\u5be6\u9ad4\u7624\u7684\u7368\u7279\u8868\u578b\u3002DNA\u8907\u88fd\u904e\u7a0b\u4e2d\uff0c\u5fae\u885b\u661f\u5e8f\u5217\u6700\u6613\u767c\u751f\u932f\u914d\uff0c\u9700\u8981\u9032\u884c\u932f\u914d\u4fee\u5fa9\uff0cdMMR\u53ef\u5c0e\u81f4\u79fb\u78bc\u7a81\u8b8a\uff0c\u5f15\u8d77\u5fae\u885b\u661f\u4e0d\u7a69\u5b9a\uff08MSI\uff09\u3002dMMR\/MSI-H\u5be6\u9ad4\u7624\u5c0d\u514d\u75ab\u6aa2\u67e5\u9ede\u6291\u5236\u5291\u6cbb\u7642\u53cd\u61c9\u826f\u597d\uff0c\u7a0b\u5e8f\u6027\u6b7b\u4ea1\u53d7\u9ad4-1\uff08PD-1\uff09\u6216\u7a0b\u5e8f\u6027\u6b7b\u4ea1\u914d\u9ad4-1\uff08PD-L1\uff09\u6291\u5236\u5291\u6cbb\u7642dMMR\/MSI-H\u5be6\u9ad4\u7624\u5177\u6709\u8f03\u9ad8\u7684\u5ba2\u89c0\u7de9\u89e3\u7387\uff08ORR\uff09\uff0c\u4e26\u4e14\u7de9\u89e3\u6301\u7e8c\u6642\u9593\u9577\u3002 \u827e\u5e15\u6d1b\u5229\u55ae\u6297\u6cbb\u7642\u665a\u671f\u5be6\u9ad4\u7624\u7684I\u671f\u7814\u7a76\u8868\u73fe\u51fa\u826f\u597d\u7684\u5b89\u5168\u6027\u548c\u6297\u816b\u7624\u6d3b\u6027\uff0c\u5728\u63a5\u53d7\u827e\u5e15\u6d1b\u5229\u55ae\u62970.3-3 mg\/kg Q3W\u7684\u6240\u6709\u60a3\u8005\u4e2d\uff0cORR\u9054\u523020%\u3002\u672c\u95dc\u9375\u7814\u7a76\u65e8\u5728\u8a55\u4f30\u827e\u5e15\u6d1b\u5229\u55ae\u6297\u55ae\u85e5\u6cbb\u7642\u4e0d\u53ef\u5207\u9664\u6216\u8f49\u79fb\u6027dMMR\/MSI-H\u5be6\u9ad4\u7624\u7684\u7642\u6548\u548c\u5b89\u5168\u6027\u3002 \u4e8c\u3001\u7814\u7a76\u8a2d\u8a08\u548c\u65b9\u6cd5 \u672c\u7814\u7a76\u70ba\u55ae\u81c2\u3001II\u671f\u95dc\u9375\u81e8\u5e8a\u7814\u7a76\uff0c\u7d0d\u5165\u4e0d\u53ef\u5207\u9664\u6216\u8f49\u79fb\u6027\u7d93\u7d44\u7e54\u75c5\u7406\u5b78\u6216\u7d30\u80de\u5b78\u78ba\u8a8d\u7684dMMR\/MSI-H\u5be6\u9ad4\u7624\u60a3\u8005\uff0c\u63a5\u53d7\u827e\u5e15\u6d1b\u5229\u55ae\u6297\u55ae\u85e5\u6cbb\u7642\uff0c\u7d66\u85e5\u65b9\u6848\u70ba200 mg\u56fa\u5b9a\u5291\u91cf\uff08\u5982\u679c\u53d7\u8a66\u8005\u9ad4\u91cd\uff1c40 kg\uff0c\u7d66\u85e5\u5291\u91cf\u70ba3 mg\/kg\uff09\uff0c\u975c\u8108\u6ef4\u6ce8\uff0c\u6bcf3\u5468\u7d66\u85e51\u6b21\u3002\u60a3\u8005\u63a5\u53d7\u827e\u5e15\u6d1b\u5229\u55ae\u6297\u6cbb\u7642\u76f4\u81f3\u75be\u75c5\u9032\u5c55\u3001\u51fa\u73fe\u4e0d\u53ef\u8010\u53d7\u7684\u6bd2\u6027\u3001\u958b\u59cb\u65b0\u7684\u6297\u816b\u7624\u6cbb\u7642\u3001\u6b7b\u4ea1\u3001\u64a4\u56de\u77e5\u60c5\u540c\u610f\u7b49\u539f\u56e0\uff0c\u6700\u9577\u6cbb\u7642\u6642\u9593\u4e0d\u8d85\u904e2\u5e74\u3002\u6cbb\u7642\u7d50\u675f\u5f8c\uff0c\u5c0d\u60a3\u8005\u9032\u884c\u751f\u5b58\u96a8\u8a2a\u3002\u7814\u7a76\u7684\u4e3b\u8981\u7d42\u9ede\u70baIRRC\u6839\u64da\u5be6\u9ad4\u816b\u7624\u7642\u6548\u8a55\u50f9\u6a19\u6e96\uff081.1\u7248\uff09\u8a55\u4f30\u7684ORR\u3002\u7814\u7a76\u8a2d\u8a08\u5982\u4e0b\u5716\u6240\u793a\u3002 \u4e09\u3001\u7814\u7a76\u7d50\u679c \u5f9e2020\u5e746\u6708\u81f32023\u5e741\u6708\uff0c\u7814\u7a76\u5171\u7d0d\u5165120\u4f8bdMMR\/MSI-H\u5be6\u9ad4\u7624\u60a3\u8005\uff0c\u5176\u4e2d\u7d50\u76f4\u8178\u764c\u60a3\u800580\u4f8b\uff0866.7%\uff09\uff0c\u80c3\u764c\u60a3\u800518\u4f8b\uff0815.0%\uff09\uff0c\u5176\u5b83\u5be6\u9ad4\u7624\u60a3\u800522\u4f8b\uff0818.3%\uff09\uff1b97.5%\u7684\u60a3\u8005\u5728\u5165\u7d44\u6642\u75be\u75c5\u5206\u671f\u70baIV\u671f\uff0c\u4e2d\u4f4d\u6cbb\u7642\u7dda\u6578\u70ba2.0\uff08\u7bc4\u570d\uff0c0\u20136\uff09\u3002 \u5728\u7642\u6548\u65b9\u9762\uff0c\u622a\u81f32023\u5e747\u670820\u65e5\uff0c\u4e2d\u4f4d\u96a8\u8a2a\u6642\u9593\u70ba13.6\u500b\u6708\uff0c\u670911\u4f8b\u60a3\u8005\u9054\u5230\u5b8c\u5168\u7de9\u89e3\uff08CR\uff09\uff0c44\u4f8b\u60a3\u8005\u9054\u5230\u90e8\u5206\u7de9\u89e3\uff08PR\uff09\uff0cORR\u70ba45.8%\uff0895% CI: 36.7%\u201355.2%\uff09\uff0c\u75be\u75c5\u63a7\u5236\u7387\uff08DCR\uff09\u70ba77.5%\uff0895% CI: 69.0%\u201384.6%\uff09\u3002\u5728\u7d50\u76f4\u8178\u764c\u60a3\u8005\u4e2d\uff0cORR\u548cDCR\u5206\u5225\u70ba42.5%\uff0895% CI: 31.5%\u201354.1%\uff09\u548c77.5%\uff0895% CI: 31.5%\u201354.1%\uff09\u3002\u4e2d\u4f4d\u7de9\u89e3\u6301\u7e8c\u6642\u9593\uff08DoR\uff09\u5c1a\u672a\u9054\u5230\uff0c6\u500b\u6708\u548c12\u500b\u6708DoR\u7387\u5206\u5225\u70ba100%\u548c97.4%\uff1b\u4e2d\u4f4d\u7121\u9032\u5c55\u751f\u5b58\u671f\uff08PFS\uff09\u548c\u4e2d\u4f4d\u7e3d\u751f\u5b58\u671f\uff08OS\uff09\u672a\u9054\u5230\u3002\u7de9\u89e3\u60a3\u8005\u7684\u9776\u75c5\u7076\u6700\u4f73\u8b8a\u5316\u60c5\u6cc1\u5982\u4e0b\u5716\u6240\u793a\u3002 \u56db\u3001\u5c0f\u7d50 \u827e\u5e15\u6d1b\u5229\u55ae\u6297\u55ae\u85e5\u6cbb\u7642\u4e0d\u53ef\u5207\u9664\u6216\u8f49\u79fb\u6027dMMR\/MSI-H\u5be6\u9ad4\u7624\u5177\u6709\u826f\u597d\u7684\u7642\u6548\u548c\u5b89\u5168\u6027\u3002\u9f4a\u9b6f\u88fd\u85e5\u827e\u5e15\u6d1b\u5229\u55ae\u6297\u4e0a\u5e02\u7533\u8acb\u5df2\u65bc\u4eca\u5e749\u6708\u7372\u5f97CDE\u53d7\u7406\u3002   \u53c3\u8003\u6587\u737b\uff1a   1. Bhamidipati D, Subbiah V. Tumor-agnostic drug development in dMMR\/MSI-H solid tumors. Trends Cancer. 2023;9(10):828-839.   2. Le DT, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.   3. Li J, et al. Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair\/microsatellite instability high solid tumors. J Hematol Oncol. 2021;14(1):95.   4. Huang Z, et al. A first-in-human, open-label, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, pharmacokinetics\/pharmacodynamics, and antitumor activity of QL1604, a humanized anti-PD-1 mAb, in patients with advanced or metastatic solid tumors. Front Immunol. 2023;14:1258573.    \u00a0","og_url":"https:\/\/pingtungtimes.com.tw\/?p=202833","og_site_name":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","article_publisher":"https:\/\/www.facebook.com\/pingtungnews","article_published_time":"2023-12-06T08:47:00+00:00","og_image":[{"width":400,"height":142,"url":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/12\/QILU_logo.jpg","type":"image\/jpeg"}],"author":"\u7f8e\u901a\u793e","twitter_card":"summary_large_image","twitter_misc":{"\u4f5c\u8005:":"\u7f8e\u901a\u793e","\u9810\u4f30\u95b1\u8b80\u6642\u9593":"1 \u5206\u9418"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/pingtungtimes.com.tw\/?p=202833#article","isPartOf":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=202833"},"author":{"name":"\u7f8e\u901a\u793e","@id":"https:\/\/pingtungtimes.com.tw\/#\/schema\/person\/683b937f29ec1537972f6c41e22a2cf3"},"headline":"\u5ba2\u89c0\u7de9\u89e3\u7387\u905445.8%\uff0c\u9f4a\u9b6f\u88fd\u85e5\u827e\u5e15\u6d1b\u5229\u55ae\u6297\u55ae\u85e5\u6cbb\u7642\u665a\u671f\u5be6\u9ad4\u7624II\u671f\u7814\u7a76\u7d50\u679c\u5728ESMO\u4e9e\u6d32\u5e74\u6703\u516c\u4f48","datePublished":"2023-12-06T08:47:00+00:00","mainEntityOfPage":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=202833"},"wordCount":162,"publisher":{"@id":"https:\/\/pingtungtimes.com.tw\/#organization"},"image":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=202833#primaryimage"},"thumbnailUrl":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/12\/QILU_logo.jpg","articleSection":["\u7f8e\u901a\u793e"],"inLanguage":"zh-TW"},{"@type":"WebPage","@id":"https:\/\/pingtungtimes.com.tw\/?p=202833","url":"https:\/\/pingtungtimes.com.tw\/?p=202833","name":"\u5ba2\u89c0\u7de9\u89e3\u7387\u905445.8%\uff0c\u9f4a\u9b6f\u88fd\u85e5\u827e\u5e15\u6d1b\u5229\u55ae\u6297\u55ae\u85e5\u6cbb\u7642\u665a\u671f\u5be6\u9ad4\u7624II\u671f\u7814\u7a76\u7d50\u679c\u5728ESMO\u4e9e\u6d32\u5e74\u6703\u516c\u4f48 - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","isPartOf":{"@id":"https:\/\/pingtungtimes.com.tw\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=202833#primaryimage"},"image":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=202833#primaryimage"},"thumbnailUrl":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/12\/QILU_logo.jpg","datePublished":"2023-12-06T08:47:00+00:00","description":"\u6fdf\u53572023\u5e7412\u67086\u65e5 \/\u7f8e\u901a\u793e\/ -- 12\u67081\u81f33\u65e5\uff0c\u57282023\u5e74\u6b50\u6d32\u816b\u7624\u5167\u79d1\u5b78\u6703\u4e9e\u6d32\u5e74\u6703\uff08ESMO Asia\uff09\u4e0a\uff0c\u9f4a\u9b6f\u88fd\u85e5\u4ee5\u58c1\u5831\u5f62\u5f0f\u5831\u544a\u4e861\u985e\u65b0\u85e5\u827e\u5e15\u6d1b\u5229\u55ae\u6297\uff08QL1604\uff09\u55ae\u85e5\u6cbb\u7642\u4e0d\u53ef\u5207\u9664\u6216\u8f49\u79fb\u6027dMMR\/MSI-H\u5be6\u9ad4\u7624\u7684\u55ae\u81c2\u3001II\u671f\u95dc\u9375\u81e8\u5e8a\u7814\u7a76\u6700\u65b0\u7d50\u679c\u3002\u4e3b\u8981\u7814\u7a76\u8005\u70ba\u5fa9\u65e6\u5927\u5b78\u9644\u5c6c\u816b\u7624\u91ab\u9662\u90ed\u5049\u528d\u6559\u6388\u548c\u56db\u5ddd\u5927\u5b78\u83ef\u897f\u91ab\u9662\u7562\u92d2\u6559\u6388\u3002 \u827e\u5e15\u6d1b\u5229\u55ae\u6297\u662f\u4e00\u7a2e\u8207PD-1\u7d50\u5408\u7684\u9ad8\u9078\u64c7\u6027\u4eba\u6e90\u5316\u55ae\u514b\u9686\u6297\u9ad4\u3002\u7814\u7a76\u7d50\u679c\u986f\u793a\uff0c\u827e\u5e15\u6d1b\u5229\u55ae\u6297\u55ae\u85e5\u6cbb\u7642\u4e0d\u53ef\u5207\u9664\u6216\u8f49\u79fb\u6027dMMR\/MSI-H\u5be6\u9ad4\u7624\u5177\u6709\u826f\u597d\u7684\u7642\u6548\uff0c\u7368\u7acb\u5f71\u50cf\u8a55\u4f30\u59d4\u54e1\u6703\uff08IRRC\uff09\u8a55\u4f30\u7684\u5168\u4eba\u7fa4\u5ba2\u89c0\u7de9\u89e3\u7387\uff08ORR\uff09\u70ba45.8% (95%CI\uff0c 36.7-55.2)\uff0c\u8d85\u904e\u9810\u8a2d\u4e3b\u8981\u7814\u7a76\u7d42\u9ede\u3002 \u4e00\u3001\u7814\u7a76\u80cc\u666f DNA\u932f\u914d\u4fee\u5fa9\u7f3a\u9677\uff08dMMR\uff09\u6216\u9ad8\u5ea6\u5fae\u885b\u661f\u4e0d\u7a69\u5b9a\uff08MSI-H\uff09\u662f\u5be6\u9ad4\u7624\u7684\u7368\u7279\u8868\u578b\u3002DNA\u8907\u88fd\u904e\u7a0b\u4e2d\uff0c\u5fae\u885b\u661f\u5e8f\u5217\u6700\u6613\u767c\u751f\u932f\u914d\uff0c\u9700\u8981\u9032\u884c\u932f\u914d\u4fee\u5fa9\uff0cdMMR\u53ef\u5c0e\u81f4\u79fb\u78bc\u7a81\u8b8a\uff0c\u5f15\u8d77\u5fae\u885b\u661f\u4e0d\u7a69\u5b9a\uff08MSI\uff09\u3002dMMR\/MSI-H\u5be6\u9ad4\u7624\u5c0d\u514d\u75ab\u6aa2\u67e5\u9ede\u6291\u5236\u5291\u6cbb\u7642\u53cd\u61c9\u826f\u597d\uff0c\u7a0b\u5e8f\u6027\u6b7b\u4ea1\u53d7\u9ad4-1\uff08PD-1\uff09\u6216\u7a0b\u5e8f\u6027\u6b7b\u4ea1\u914d\u9ad4-1\uff08PD-L1\uff09\u6291\u5236\u5291\u6cbb\u7642dMMR\/MSI-H\u5be6\u9ad4\u7624\u5177\u6709\u8f03\u9ad8\u7684\u5ba2\u89c0\u7de9\u89e3\u7387\uff08ORR\uff09\uff0c\u4e26\u4e14\u7de9\u89e3\u6301\u7e8c\u6642\u9593\u9577\u3002 \u827e\u5e15\u6d1b\u5229\u55ae\u6297\u6cbb\u7642\u665a\u671f\u5be6\u9ad4\u7624\u7684I\u671f\u7814\u7a76\u8868\u73fe\u51fa\u826f\u597d\u7684\u5b89\u5168\u6027\u548c\u6297\u816b\u7624\u6d3b\u6027\uff0c\u5728\u63a5\u53d7\u827e\u5e15\u6d1b\u5229\u55ae\u62970.3-3 mg\/kg Q3W\u7684\u6240\u6709\u60a3\u8005\u4e2d\uff0cORR\u9054\u523020%\u3002\u672c\u95dc\u9375\u7814\u7a76\u65e8\u5728\u8a55\u4f30\u827e\u5e15\u6d1b\u5229\u55ae\u6297\u55ae\u85e5\u6cbb\u7642\u4e0d\u53ef\u5207\u9664\u6216\u8f49\u79fb\u6027dMMR\/MSI-H\u5be6\u9ad4\u7624\u7684\u7642\u6548\u548c\u5b89\u5168\u6027\u3002 \u4e8c\u3001\u7814\u7a76\u8a2d\u8a08\u548c\u65b9\u6cd5 \u672c\u7814\u7a76\u70ba\u55ae\u81c2\u3001II\u671f\u95dc\u9375\u81e8\u5e8a\u7814\u7a76\uff0c\u7d0d\u5165\u4e0d\u53ef\u5207\u9664\u6216\u8f49\u79fb\u6027\u7d93\u7d44\u7e54\u75c5\u7406\u5b78\u6216\u7d30\u80de\u5b78\u78ba\u8a8d\u7684dMMR\/MSI-H\u5be6\u9ad4\u7624\u60a3\u8005\uff0c\u63a5\u53d7\u827e\u5e15\u6d1b\u5229\u55ae\u6297\u55ae\u85e5\u6cbb\u7642\uff0c\u7d66\u85e5\u65b9\u6848\u70ba200 mg\u56fa\u5b9a\u5291\u91cf\uff08\u5982\u679c\u53d7\u8a66\u8005\u9ad4\u91cd\uff1c40 kg\uff0c\u7d66\u85e5\u5291\u91cf\u70ba3 mg\/kg\uff09\uff0c\u975c\u8108\u6ef4\u6ce8\uff0c\u6bcf3\u5468\u7d66\u85e51\u6b21\u3002\u60a3\u8005\u63a5\u53d7\u827e\u5e15\u6d1b\u5229\u55ae\u6297\u6cbb\u7642\u76f4\u81f3\u75be\u75c5\u9032\u5c55\u3001\u51fa\u73fe\u4e0d\u53ef\u8010\u53d7\u7684\u6bd2\u6027\u3001\u958b\u59cb\u65b0\u7684\u6297\u816b\u7624\u6cbb\u7642\u3001\u6b7b\u4ea1\u3001\u64a4\u56de\u77e5\u60c5\u540c\u610f\u7b49\u539f\u56e0\uff0c\u6700\u9577\u6cbb\u7642\u6642\u9593\u4e0d\u8d85\u904e2\u5e74\u3002\u6cbb\u7642\u7d50\u675f\u5f8c\uff0c\u5c0d\u60a3\u8005\u9032\u884c\u751f\u5b58\u96a8\u8a2a\u3002\u7814\u7a76\u7684\u4e3b\u8981\u7d42\u9ede\u70baIRRC\u6839\u64da\u5be6\u9ad4\u816b\u7624\u7642\u6548\u8a55\u50f9\u6a19\u6e96\uff081.1\u7248\uff09\u8a55\u4f30\u7684ORR\u3002\u7814\u7a76\u8a2d\u8a08\u5982\u4e0b\u5716\u6240\u793a\u3002 \u4e09\u3001\u7814\u7a76\u7d50\u679c \u5f9e2020\u5e746\u6708\u81f32023\u5e741\u6708\uff0c\u7814\u7a76\u5171\u7d0d\u5165120\u4f8bdMMR\/MSI-H\u5be6\u9ad4\u7624\u60a3\u8005\uff0c\u5176\u4e2d\u7d50\u76f4\u8178\u764c\u60a3\u800580\u4f8b\uff0866.7%\uff09\uff0c\u80c3\u764c\u60a3\u800518\u4f8b\uff0815.0%\uff09\uff0c\u5176\u5b83\u5be6\u9ad4\u7624\u60a3\u800522\u4f8b\uff0818.3%\uff09\uff1b97.5%\u7684\u60a3\u8005\u5728\u5165\u7d44\u6642\u75be\u75c5\u5206\u671f\u70baIV\u671f\uff0c\u4e2d\u4f4d\u6cbb\u7642\u7dda\u6578\u70ba2.0\uff08\u7bc4\u570d\uff0c0\u20136\uff09\u3002 \u5728\u7642\u6548\u65b9\u9762\uff0c\u622a\u81f32023\u5e747\u670820\u65e5\uff0c\u4e2d\u4f4d\u96a8\u8a2a\u6642\u9593\u70ba13.6\u500b\u6708\uff0c\u670911\u4f8b\u60a3\u8005\u9054\u5230\u5b8c\u5168\u7de9\u89e3\uff08CR\uff09\uff0c44\u4f8b\u60a3\u8005\u9054\u5230\u90e8\u5206\u7de9\u89e3\uff08PR\uff09\uff0cORR\u70ba45.8%\uff0895% CI: 36.7%\u201355.2%\uff09\uff0c\u75be\u75c5\u63a7\u5236\u7387\uff08DCR\uff09\u70ba77.5%\uff0895% CI: 69.0%\u201384.6%\uff09\u3002\u5728\u7d50\u76f4\u8178\u764c\u60a3\u8005\u4e2d\uff0cORR\u548cDCR\u5206\u5225\u70ba42.5%\uff0895% CI: 31.5%\u201354.1%\uff09\u548c77.5%\uff0895% CI: 31.5%\u201354.1%\uff09\u3002\u4e2d\u4f4d\u7de9\u89e3\u6301\u7e8c\u6642\u9593\uff08DoR\uff09\u5c1a\u672a\u9054\u5230\uff0c6\u500b\u6708\u548c12\u500b\u6708DoR\u7387\u5206\u5225\u70ba100%\u548c97.4%\uff1b\u4e2d\u4f4d\u7121\u9032\u5c55\u751f\u5b58\u671f\uff08PFS\uff09\u548c\u4e2d\u4f4d\u7e3d\u751f\u5b58\u671f\uff08OS\uff09\u672a\u9054\u5230\u3002\u7de9\u89e3\u60a3\u8005\u7684\u9776\u75c5\u7076\u6700\u4f73\u8b8a\u5316\u60c5\u6cc1\u5982\u4e0b\u5716\u6240\u793a\u3002 \u56db\u3001\u5c0f\u7d50 \u827e\u5e15\u6d1b\u5229\u55ae\u6297\u55ae\u85e5\u6cbb\u7642\u4e0d\u53ef\u5207\u9664\u6216\u8f49\u79fb\u6027dMMR\/MSI-H\u5be6\u9ad4\u7624\u5177\u6709\u826f\u597d\u7684\u7642\u6548\u548c\u5b89\u5168\u6027\u3002\u9f4a\u9b6f\u88fd\u85e5\u827e\u5e15\u6d1b\u5229\u55ae\u6297\u4e0a\u5e02\u7533\u8acb\u5df2\u65bc\u4eca\u5e749\u6708\u7372\u5f97CDE\u53d7\u7406\u3002 \u53c3\u8003\u6587\u737b\uff1a 1. Bhamidipati D, Subbiah V. Tumor-agnostic drug development in dMMR\/MSI-H solid tumors. Trends Cancer. 2023;9(10):828-839. 2. Le DT, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20. 3. Li J, et al. Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair\/microsatellite instability high solid tumors. J Hematol Oncol. 2021;14(1):95. 4. Huang Z, et al. A first-in-human, open-label, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, pharmacokinetics\/pharmacodynamics, and antitumor activity of QL1604, a humanized anti-PD-1 mAb, in patients with advanced or metastatic solid tumors. Front Immunol. 2023;14:1258573. \u00a0","breadcrumb":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=202833#breadcrumb"},"inLanguage":"zh-TW","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pingtungtimes.com.tw\/?p=202833"]}]},{"@type":"ImageObject","inLanguage":"zh-TW","@id":"https:\/\/pingtungtimes.com.tw\/?p=202833#primaryimage","url":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/12\/QILU_logo.jpg","contentUrl":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/12\/QILU_logo.jpg","width":400,"height":142},{"@type":"BreadcrumbList","@id":"https:\/\/pingtungtimes.com.tw\/?p=202833#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"\u9996\u9801","item":"https:\/\/pingtungtimes.com.tw\/"},{"@type":"ListItem","position":2,"name":"\u5ba2\u89c0\u7de9\u89e3\u7387\u905445.8%\uff0c\u9f4a\u9b6f\u88fd\u85e5\u827e\u5e15\u6d1b\u5229\u55ae\u6297\u55ae\u85e5\u6cbb\u7642\u665a\u671f\u5be6\u9ad4\u7624II\u671f\u7814\u7a76\u7d50\u679c\u5728ESMO\u4e9e\u6d32\u5e74\u6703\u516c\u4f48"}]},{"@type":"WebSite","@id":"https:\/\/pingtungtimes.com.tw\/#website","url":"https:\/\/pingtungtimes.com.tw\/","name":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","description":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831PingtungTimes\uff0c\u6700\u95dc\u5fc3\u5728\u5730\u7684\u5a92\u9ad4","publisher":{"@id":"https:\/\/pingtungtimes.com.tw\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pingtungtimes.com.tw\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"zh-TW"},{"@type":"Organization","@id":"https:\/\/pingtungtimes.com.tw\/#organization","name":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","url":"https:\/\/pingtungtimes.com.tw\/","logo":{"@type":"ImageObject","inLanguage":"zh-TW","@id":"https:\/\/pingtungtimes.com.tw\/#\/schema\/logo\/image\/","url":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/02\/logo-150.png","contentUrl":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/02\/logo-150.png","width":150,"height":150,"caption":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831"},"image":{"@id":"https:\/\/pingtungtimes.com.tw\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/pingtungnews"]},{"@type":"Person","@id":"https:\/\/pingtungtimes.com.tw\/#\/schema\/person\/683b937f29ec1537972f6c41e22a2cf3","name":"\u7f8e\u901a\u793e","image":{"@type":"ImageObject","inLanguage":"zh-TW","@id":"https:\/\/secure.gravatar.com\/avatar\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g","caption":"\u7f8e\u901a\u793e"},"url":"https:\/\/pingtungtimes.com.tw\/?author=16"}]}},"_links":{"self":[{"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/202833","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=202833"}],"version-history":[{"count":0,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/202833\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/media\/202834"}],"wp:attachment":[{"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=202833"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=202833"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=202833"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}